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The Jak/STAT pathway is used by IFN-a and other cytokines to
transduce regulatory signals inside the cell (Darnell, 1997). In this
pathway, receptor-associated, ligand-activated kinases phosphoryl-
ate STAT proteins on tyrosine residues. Once modified and acti-
vated, dimerized STATs translocate into the nucleus to initiate
trascriptional regulation (Darnell, 1997), affecting the growth,
differentiation and function of various cell types (for review see
Herberman, 1997). The signalling pathways employing MEK and
ERK are critical in growth factors signalling (Pages et al, 1993;
Cowley et al, 1994; Seger and Krebs, 1995; Pumiglia and Decker,
1997; Madhani and Fink, 1998). MEK is activated by upstream
molecules, among which Ras and Raf play a fundamental role.
Due to the critical involvement of the MEK/ERK pathway in
the events controlling cellular proliferation, and to the well docu-
mented antiproliferative effect of IFN-a (Pfeffer et al, 1998), we
tested the effects of IFN-a on the MEK/ERK pathway, in an
attempt to provide a molecular basis for the anti-proliferative
activity of this multifunctional cytokine. We demonstrate here
that recombinant human IFN-a2b reduces the phosphorylation
and activity of both MEK1 and ERK1/2 through a Ras/Raf-
independent mechanism.
MATERIALS AND METHODS
Transformed cell lines and reagents
The CD4+ lymphoblastoid cell lines Jurkat, SupT1, H9 and CEM,
and the monocytoid cell line U937 (all from ATCC, Manassas,
VA, USA) were maintained in complete RPMI medium supple-
mented with 10% fetal bovine serum (GIBCO/BRL, Gaithersburg,
MD, USA). Treatment with IFN-a was performed at the indicated
concentrations by culturing the cells at 3–5 ´ 105 cells ml–1 in
complete RPMI medium. Recombinant human IFN-a2b was from
Biosidus (Buenos Aires, Argentina). The protein was > 98% pure
as assessed by gel electrophoresis. IFN-a antiviral activity was
assessed in culture by the standard biological test by using MDBK
cells and vescicular stomatitis virus, as previously described
(Rubinstein et al, 1981). The activity was in the range of 2–3 ´ 108
U mg–1. Anti-IFN-a polyclonal antibodies were from Biosource
International, Camarillo, CA, USA. The MEK1 inhibitor PD98059
was purchased from New England Biolabs (Beverly, MA, USA).
Western blot
Aliquots of cells were lysed in a buffer containing 20 mmol l–1
Tris-Cl (pH 7.5), 150 mmol l–1 NaCl, 1 mmol l–1 EDTA, 1 mmol l–1
EGTA, 1% Triton X-100, 2.5 mmol l–1 sodium pyrophosphate,
1 mmol l–1 b-glycerolphosphate, 1 mmol l–1 Na3VO4, 1 mg ml–1
leupeptin, 1 mmol l–1 PMSF. The lysate was incubated at 4°C for
15 min with moderate shaking. Cell debris were pelleted by
centrifugation, and the supernatant collected and frozen. 25 mg of
whole-cell lysate were run on a 12% SDS-PAGE in Tris-glycine
buffer. The gels were transferred to a PVDF membrane using a
SemiDry blotting apparatus (Pharmacia, Piscataway, NJ, USA) in
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25 mmol l–1 Tris, 192 mmol l–1 glycine, 20% methanol. After
blocking in Blotto-Tween (10 mmol l–1 Tris-Cl (pH 7.5), 0.9%
NaCl, 0.1% Tween-20, 5% Nonfat Dry Milk), the membranes
were first probed with antibodies detecting phospho-proteins
(according to the manufacturer’s instructions) and developed
using the ECL Plus Kit from Amersham (Arlington Heights, IL,
USA). Subsequently, the blots were stripped in 0.1 mol l–1 glycine
(pH 2.9), blocked in Blotto-Tween and re-probed with antibodies
detecting total protein levels. Anti-ERK1/2, anti-MEK1, anti-Raf-
1, anti-p38 and anti-b-actin antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-phospho-ERK1/2,
anti-phospho-MEK1/2 and anti-phospho-p38 antibodies were
from New England Biolabs (Beverly, MA, USA). The effect of
IFN-a on the rate of re-phosphorylation of ERK1/2 in Jurkat cells
was investigated by either of two protocols. In the first procedure,
the cells were cultured for 24–48 h in medium supplemented
with 0.5% serum, and then re-stimulated with 10% serum (for
0–30 min) in the presence or absence of IFN-a. In the second
procedure, the cells were cultured for 24–48 h in 0.5% serum with
or without IFN-a, and subsequently re-stimulated with 10% serum
alone (for 0–30 min). Whole-cell lysates were prepared as
described above, immediately after collection of each aliquot.
Immunoprecipitation and kinase assay for MEK and
ERK activity
The ERK1/2 and MEK1/2 kinase assays were performed using
kits available from New England Biolabs, following the manufac-
turer’s instructions. Quantification of all blots was performed by
densitometric analysis using the Molecular Analyst® software
(version 2.1) from BioRad (Hercules, CA, USA).
Assessment of in vivo p21ras activity
The assay to assess the GTPase activity in IFN-a-treated vs
untreated cells was performed as previously described (Burgering
et al, 1991) with few minor modifications. Cells were grown for
24–48 h with or without 30 ng ml–1 IFN-a. Subsequently, the cells
were labelled with 40 mCi ml–1 carrier-free [32P]H3PO4 (ICN, Costa
Mesa, CA, USA) for 3 h at 37°C in RPMI 1640 without sodium
phosphate. Control aliquots were removed, and the remaining cells
were stimulated by cross-linking with anti-CD3/CD4 antibodies as
described (Kirk and Miller, 1998). Cells were washed in ice-cold
PBS to remove the unincorporated radioactive phosphate, and then
lysed in 500 ml of ice-cold lysis buffer containing 50 mmol l–1
Tris-Cl (pH 7.5), 1% Triton X-114, 150 mmol l–1 NaCl, 5 mmol l–1
MgCl2, 10 mg ml–1 leupeptin, 10 mg ml–1 aprotinin, 1 mmol l–1
PMSF, 100 mmol l–1 GTP, 100 mmol l–1 GDP, 1 mmol l–1 NaPO4
(pH 7.5). After 15 min on ice, nuclei were removed by centrifuga-
tion at 4°C. In order to recover the membrane-associated (active)
fraction of Ras, the lysate was incubated at 37°C for 3 min
followed by a brief centrifugation at room temperature. The upper
aqueous phase was removed and the lower Triton phase diluted
10-fold with lysis buffer without Triton X-114. An equal number
of cpm were incubated in a 500-ml reaction with 20 ml of agarose-
conjugated anti-p21 antibody (clone Y13-259, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 3 h at 4°C with end-
over-end agitation. The immunoprecipitates were washed eight
times with 1 ml of wash buffer containing 50 mmol l–1 Tris-Cl
(pH 7.5), 500 mmol l–1 NaCl, 5 mmol l–1 MgCl2, 0.1% Triton X-100,
0.005% SDS. Ras-bound nucleotides were eluted in 20 ml of
elution buffer (40 mmol l–1 EDTA, 40 mmol l–1 Tris-Cl pH 7.5, 4%
SDS, 1 mmol l–1 GTP, 1 mmol l–1 GDP) by incubation at 68°C for
20 min. An equal number of cpm were spotted on PEI-Cellulose
plates (JT Baker, Phillipsburg, NJ, USA) and developed for 1 h in
1.2 mol l–1 ammonium formate, 0.8 mol l–1 HCl. The plates were
air-dried and exposed to a Storm PhosphorImager for quantifica-
tion of the GTP and GDP spots.
In vitro Raf activity assay
Raf-1 was immunoprecipitated from whole cell lysates using
specific antibodies (Santa Cruz). The immuno-complexes were
washed three times in lysis buffer and then in kinase assay buffer
(25 mmol l–1 Tris-Cl (pH 7.5), 5 mmol l–1 b-glycerolphosphate,
2 mmol l–1 DTT, 0.1 mmol l–1 Na3VO4 and 10 mmol l–1 MgCl2).
Kinase reactions were performed by incubating the immuno-
complexes at 30°C for 30 min in the presence of 200 mmol l–1 ATP
and 2 mg of the specific substrate (MEK 1, from Santa Cruz) in
kinase buffer. Reactions were stopped with SDS-PAGE loading
buffer and run on a 12% SDS-PAGE. The gels were transferred to
PVDF and probed with an anti-phospho-MEK1/2 antibody. Blots
were subsequently stripped and reprobed with an anti-Raf-1 anti-
body to confirm the presence of equal amounts of Raf-1 in all
lanes.
RESULTS
IFN-a treatment reduces proliferative capacity of
transformed cell lines
The anti-proliferative effect of IFN-a was first determined in
several lymphocytoid transformed CD4+ cell lines, namely Jurkat,
U937, SupT1, H9 and CEM. As reported in Figure 1A, all cell
lines were sensitive to treatment with IFN-a, displaying a reduc-
tion in proliferation ranging from 10–25% at day 2 to 35–40% at
day 6 of culture. The dose- and time-dependent anti-proliferative
effect was also assessed. Cultures of Jurkat cells were maintained
for 6 days in the presence of IFN-a at a concentration range of
0.1–100 ng ml–1 (Figure 1B). This experiment shows that by day 6
concentrations of IFN-a as low as 0.5 ng ml–1 (corresponding to
150 IU ml–1) had a remarkable inhibitory effect on the prolifera-
tion of Jurkat cells. Since a concentration of IFN-a of
10–50 ng ml–1 was sufficient to reduce cell proliferation by about
30% at day 4 and about 50% at day 6, all subsequent experiments
were carried out by culturing the cells in the presence of 30 ng ml–1
of IFN-a.
Treatment with IFN-a reduces the levels of
phosphorylation and activity of MEK1 and ERK1/2 in
Jurkat and U937
Once activated by autophosphorylation or upstream kinases
(Gomez and Cohen, 1991; Dent et al, 1992; Howe et al, 1992;
Kyriakis et al, 1992; Ahn et al, 1993; Itoh et al, 1993; Matsuda et
al, 1993; Posada et al, 1993; Gardner et al, 1994; Haystead et al,
1994; Papin et al, 1998), MEK activity is the main upstream mech-
anism leading to phosphorylation of both tyrosine and serine/
threonine residues and subsequent activation of ERK (Seger and
Krebs, 1995). This, in turn, results in the regulation of a large
number of proteins both in the cytoplasm and, following ERK
translocation, in the nucleus (Khokhlatchev et al, 1998).534 F Romerio et al
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Due to its importance in the process leading to cellular prolifer-
ation, we first determined the effect of IFN-a on MEK phosphoryl-
ation and kinase activity. Preliminary experiments carried out in
our laboratory have indicated that the use of a Triton X-100-based
buffer to prepare whole-cell lysates (see Materials and Methods
for details) allows the recovery of greater than 95% of MEK1 and
ERK1/2 in the soluble fraction (not shown). In addition, side-by-
side experiments have indicated that preparation of whole-cell
lysates with a Triton X-100-based buffer or by boiling the cells in
SDS-PAGE sample buffer yields identical results (not shown).
Since the former procedure is carried out in native conditions and
allows the recovery of enzymatically active proteins that can be
used in kinase assays, we have employed this method for the
preparation of cell lysates throughout this study (except for those
used to assess Ras activity, see Materials and Methods).
As representative of transformed CD4+ cell lines, we selected a
monocytoid cell line (U937) and a lymphocytoid cell line (Jurkat).
Upon treatment with IFN-a for 48 h, we observed a drastic reduc-
tion in MEK1 phosphorylation at Ser 217 and Ser 221 in both cell
lines, as assessed by Western blot with specific antibodies (Figures
2A and 2B, upper panel). This reduced phosphorylation paralleled
a reduction in kinase activity, whereas the amount of total protein
did not change (Figures 2A and 2B, lower and middle panel,
respectively). We determined by densitometric analysis the rela-
tive intensity of each band from several independent experiments:
the mean and the standard deviation are plotted in the histograms.
Subsequently, we determined the status of phosphorylation and the
activity of the downstream kinases, ERK1/2. In agreement with
the results obtained for MEK1, we observed a drastic reduction in
ERK1/2 phosphorylation at Thr 202 and Tyr 204 in both cell lines,
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Figure 1 (A) Effect of IFN-a on the proliferation of several CD4+ cell lines.
Cells were grown for 6 days in complete RPMI medium containing 30 ng ml–1
IFN-a. Every 2 days, samples of the cultures were taken, and cell count and
viability (as determined by triypan blue exclusion) were determined. The data
shown are representative of the results obtained in four independent
experiments carried out in duplicate with Jurkat, SupT1, H9, CEM and U937.
Mean and standard deviation are shown. (B) Dose- and time-dependent anti-
proliferative effect of IFN-a on Jurkat cells. Cells were cultured for 6 days in
the presence of IFN-a (0.1–100 ng ml–1), and samples of the cultures were
taken at days 2, 4 and 6. Cell count and viability were determined by trypan
blue staining. Results are representative of four independent experiments
carried out with duplicate samples. Addition of polyclonal antibodies against
IFN-a reversed its anti-proliferative effect and during the 6 days of
experiment the number of viable cells was constantly above 95%
(not shown)
Figure 2 Treatment with IFN-a specifically reduces phosphorylation and
activity of MEK1. Western blot analysis of the phosphorylation, protein levels
and kinase activity assay of MEK1 is shown. (A) Jurkat and (B) U937 cell
lines were treated with IFN-a (30 ng ml–1) and after 48 h whole-cell extracts
were prepared as described in Methods. Equal amounts of total protein were
loaded in each lane or used to immunoprecipitate phospho-MEK1, and
subsequently analysed for the phosphorylation and activity of MEK1,
respectively. Upper panel = amounts of phosphorylated MEK1 (P-MEK1),
middle panel = total MEK1, and lower panel = activity of P-MEK1 on its
substrate, ERK2. A representative of three independent experiments with
each cell line is shown. At the bottom of the figure, a histogram is reported
with mean and standard deviation of the relative values of the densitometric
analyses from three independent experimentsIFN-a reduces MEK and ERK activity 535
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while the total amount of protein was stable (Figure 3A and 3B,
upper panel). Consistent with this result, we detected a strong
reduction in the kinase activity of ERK1/2 on the substrate Elk1 in
both cell lines (Figure 3A and 3B, lower panel). However the
protein levels of ERK1/2 remained unchanged (Figure 3A and 3B,
middle panel). Phosphorylation of another MAPK implicated in
the cell cycle regulation (namely p38) (Takenaka et al, 1998) was
not affected (Figure 4A and 4B, upper panel), thus suggesting a
specific action of IFN-a on the MEK/ERK pathway.
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Figure 3 Treatment with IFN-a specifically reduces phosphorylation and
activity of ERK1/2. Western blot analysis of the phosphorylation level, total
protein amount and kinase activity assay of ERK1/2 is shown. (A) Jurkat and
(B) U937 cell lines were treated with IFN-a (30 ng ml–1) and after 48 h
whole-cell extracts were prepared as described in Methods. Equal amounts
of total protein were loaded in each lane or used to immunoprecipitate
phospho-ERK1/2, and subsequently analysed for the phosphorylation and
activity of ERK1/2, respectively. Upper panel = amounts of phosphorylated
ERK1/2 (P-ERK1/2), middle panel = total ERK1/2, and lower panel = activity
of P-ERK1/2 on its substrate, Elk-1. A representative of three independent
experiments with each cell line is shown. At the bottom of the figure, a
histogram is reported with mean and standard deviation of the relative values
of the densitometric analyses from three independent experiments
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Figure 4 Treatment with IFN-a does not affect levels and phosphorylation
of p38. Western blot analysis of the total amount of protein and
phosphorylation level of p38 is shown (Itoh et al, 1993). (A) Jurkat and (B)
U937 cell lines were treated with IFN-a (30 ng ml–1) and after 48 h total
cellular extracts were prepared as described in Methods. Equal amounts of
total protein were loaded in each lane and subsequently analysed for the
levels and phosphorylation of p38, as described in Methods. Upper panel =
amounts of phosphorylated p38 (P-p38), middle panel = total p38, and lower
panel = b-actin. A representative of three independent experiments with each
cell line is shown. At the bottom of the figure a histogram is reported with
mean and standard deviation of the relative values of the densitometric
analyses from three independent experiments536 F Romerio et al
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Inhibition of the MEK/ERK pathway is a long-term effect
of IFN-a treatment
As other groups have shown that short-term treatment with IFN-a
can activate the MEK/ERK pathway (Arora et al, 1999; Lund et al,
1999), we also investigated the possibility that brief exposures to
IFN-a may affect the activity of MEK/ERK. When we treated
Jurkat cells with IFN-a for short periods of time (1–30 min) we
were unable to observe any increase in the phosphorylation of
ERK1/2 (not shown). However, we observed that the baseline
level of phosphorylation of ERK1/2 in normally growing Jurkat
cells was very high and possibly already reached its maximum,
raising the possibility that this could have masked the effect of
IFN-a, thereby preventing us from appreciating any increase in the
phosphorylation of ERK1/2. Therefore we designed an experiment
that could allow us to observe any stimulatory effect of IFN-a on
the phosphorylation of ERK1/2. First we cultured Jurkat cells in
low-serum medium for 24–48 h, which markedly diminished the
phosphorylation of ERK1/2, and then we tested whether short-
term exposures to IFN-a could increase the rate of re-phosphoryla-
tion of ERK1/2 upon addition of serum to the culture medium. As
shown in the upper panel of Figure 5, IFN-a has no influence on
the rate of activation of ERK1/2 after the addition of serum. In
addition, treatment of serum-deprived Jurkat cells with IFN-a
alone had no effect on the re-phosphorylation of ERK1/2 (not
shown). However, Jurkat cells cultured for 24–48 h in low-serum
medium supplemented with IFN-a showed a much slower kinetic
of re-phosphorylation of ERK1/2 upon addition of serum, as
compared to cells cultured in low-serum medium alone.
Finally, we assessed whether in our in vitro model the reduction
in the activity of MEK/ERK is a molecular phenomenon conse-
quent to – as opposed to the cause of – the diminished cellular
proliferation observed after treatment with IFN-a. For this reason,
we sought to uncouple cellular proliferation from MEK/ERK
pathway activity. First we attempted to diminish the rate of cellular
proliferation while leaving the activity of MEK/ERK unaffected,
by culturing the cells in progressively lower concentrations of
serum (not shown). Second, we attempted to block the activity
of MEK/ERK while leaving the rate of cellular proliferation
unchanged, by adding PD98059, a specific inhibitor of MEK1/2,
to the culture medium. We were unsuccessful in our attempt to
dissociate the activity of the MEK/ERK pathway from cellular
proliferation. In fact, cells cultured in the presence of both IFN-a
and PD98059 showed a dose-dependent additive effect in reducing
cellular proliferation, as compared to cells treated with IFN-a
alone (Figure 6). These data indicate that in our in vitro system
cellular proliferation requires an active and functional MEK/ERK
pathway and that IFN-a reduces cellular proliferation by inter-
fering with this pathway.
Treatment with IFN-a does not affect the activities of
Ras and Raf
The major mechanism leading to MEK activation requires the
upstream kinase, Raf-1, and GTPase, Ras (Dent et al, 1992; Howe
et al, 1992; Kyriakis et al, 1992). To determine whether IFN-a
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Figure 5 Short-term treatment of Jurkat cells with IFN-a does not affect the
rate of activation of ERK1/2 in response to serum. In the upper panel, cells
were grown in low serum for 24–48 h and subsequently re-stimulated with
serum either in the presence or the absence of IFN-a. In the lower panel,
cells were first cultured for 24–48 h in the presence or absence of IFN-a and
then re-stimulated with serum alone. As shown, the presence of IFN-a during
re-stimulation with serum does not influence the rate of re-phosphorylation of
ERK1/2, while the presence of IFN-a during serum deprivation strongly
affects the kinetic of re-activation of ERK1/2. The results shown are
representative of three independent experiments
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Figure 6 Additive effect of IFN-a and PD98059 in reducing cellular
proliferation. Jurkat cells were grown in complete RPMI medium as
described in Materials and Methods, supplemented with 30 ng ml–1 of IFN-a
and 10 or 100 mmol l–1of PD98059, or a combination of the two molecules.
At days 2 and 4 cell counts and viability were determined by trypan blue
exclusion. The data shown represent results obtained in four independent
experiments carried out with duplicate samples. Mean and standard
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Figure 7 Treatment with IFN-a does not affect the kinase activity of Raf-1.
Jurkat cells were grown for 24 and 48 h in complete RPMI medium containing
30 ng ml–1 IFN-a. Equal amounts of whole cell lysate were used to
immunoprecipitate Raf from IFN-a-treated and control cells, and
subsequently to determine the kinase activity of Raf using MEK1 as a
substrate (upper panel). The lower panel shows that equal amounts of Raf
were present in the immunocomplexes from treated and untreated cells. The
results shown are representative of five independent experimentsIFN-a reduces MEK and ERK activity 537
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reduces MEK/ERK activity through a Ras/Raf-dependent mecha-
nism, we assessed the activity of Raf-1 and Ras recovered from
IFN-treated Jurkat cells. As shown in Figure 7 (upper panel),
kinase activity of Raf-1 recovered from Jurkat cells treated with
IFN-a for 24 and 48 h was not altered as compared to untreated
controls. The lower panel (Figure 7) shows that identical amounts
of Raf-1 protein were immunoprecipitated from all samples.
Consistent with the results obtained for Raf, we observed
similar amounts of GTP-bound, active Ras immunoprecipitated
from lysates of IFN-treated or control cells after stimulation with
cross-linked anti-CD3/CD4 antibodies (Figure 8). Similar results
have been obtained using PMA (100 ng ml–1) to induce transient
activation of Ras (not shown). Western blot assays confirmed that
treatment with IFN-a does not alter the expression of Ras (not
shown). Overall, these results point toward a mechanism respon-
sible for the IFN-mediated reduction of MEK/ERK activity, which
bypasses the upstream molecules, Ras and Raf-1.
DISCUSSION
Here we have shown that treatment with IFN-a reduces the phos-
phorylation of MEK1 and ERK1/2 in transformed cell lines. The
diminished phosphorylation was observed after 24–48 h and was
paralleled by reduced enzymatic activity as assessed by phos-
phorylation assays of specific substrates (namely ERK2 and E1k-1
for MEK1 and ERK1/2, respectively). In addition, since Western
blot analysis demonstrated the same amount of MEK and ERK
proteins, the results cannot be attributed to a direct mechanism
whereby IFN-a reduces the expression of MEK1 and ERK1/2.
Moreover, the reduction in the activity of the MEK/ERK pathway
was associated with a reduction of proliferative capacity of trans-
formed cell lines. Given the fundamental importance of this
pathway in regulating cell proliferation, this reduction in the
activity of MEK/ERK may constitute a molecular mechanism for
the anti-proliferative activity of IFN-a. Finally, the decrease
MEK/ERK activity was not associated with reduction of Ras/Raf
function.
Although the Jak/STAT pathway is clearly important in the
establishment of the IFN-mediated effects, a number of recent
studies suggest that additional signalling pathways may also be
important for IFN-dependent biological response. To this regard,
type I IFNs have been shown to stimulate Raf and ERK activation
in a Jak-dependent, but Ras-independent manner (Stancato et al,
1997; Sakatsume al, 1998). The cross-talk between the Jak/STAT
and MEK/ERK pathway is further demonstrated by observation
that stimulation with IFN-b can result in activation of ERK and its
direct association with STAT1, as revealed by co-immunoprecipi-
tation studies (David et al, 1995). In other reports IFN-a has been
shown to directly activate MEK/ERK (Arora et al, 1999; Lund et
al, 1999) and phosphatidylinositol 3-kinase (PI-3K) (Uddin et al,
1997). In contrast, treatment of cells with the PI-3K inhibitor wort-
mannin appears to inhibit type I IFN-regulated ERK activation
(Uddin et al, 1997). It is important to note that all these experi-
ments analysed events occurring very early after the stimulation of
cells with IFN-a. Certainly, this is a notable contribution to the
understanding of all the molecular players involved in the estab-
lishment of the IFN-mediated effects. Nonetheless, biochemical
and functional characterization of the long-term events occurring
upon treatment with IFN-a are also needed to better comprehend
the mechanisms of action of this multifunctional cytokine.
A number of experiments investigated the long-term molecular
effects of exposure to IFN-a. Examples of such effects include
modulation of PKC isotypes, down-regulation of c-myc and
cyclin-A, and hypophosphorylation of the retinoblastoma gene
(Resnitky et al, 1992). In addition, it was demonstrated that tran-
scriptionally active STAT1 is required for the anti-proliferative
effect of IFN-a, and this anti-proliferative activity was established
several hours after initial treatment of the cells with IFN-a
(Bromberg et al, 1996). Proliferation of STAT1-deficient cells was
not inhibited by IFN-a (Bromberg et al, 1996; Grimley et al,
1998). Finally, failure of IFN-a to reduce proliferative ability of a
cutaneous T-cell lymphoma (CTCL) cell line was correlated to
lack of STAT1 expression (Sun et al, 1998). These observations
strongly suggest that: i) activation of the Jak/STAT pathway is
crucial to establish the anti-proliferative effect of IFN-a; ii) it is
likely that events occurring downstream of this pathway, such as
effects on the rate of protein synthesis, are relevant for the
establishment of IFN-mediated anti-proliferative effect.
Our results show that exposure to IFN-a results in an impair-
ment of the MEK/ERK pathway, which in turn causes a reduction
in rate of cellular proliferation. This conclusion is supported by a
recent publication showing that a blockade in the MAPK pathway
by a selective inhibitor of MEK prevents the growth of colon
carcinomas in mice, and further demonstrating that cellular
proliferation strongly requires an active MEK/ERK pathway
(Sebolt-Leopold et al, 1999).
Several hypotheses can account for the indirect (long-term)
effect of the Jak/STAT pathway on the MEK/ERK signalling
cascade. A specific phosphatase – such as PP2A (Anderson et al,
1990) – may be induced by IFN-a, thus resulting in the inactiva-
tion of MEK or ERK. Another possibility is that IFN-a may regu-
late the expression of docking proteins (Pawson and Scott, 1997;
Schaeffer et al, 1998; Whitmarsh and Davis, 1998), eventually
affecting the interaction between MEK and ERK, or between
MEK and upstream kinases. Understanding the exact mechanism
is important for our comprehension of the proper function of
IFN-a and possibly to develop novel targets to strengthen the
IFN-mediated anti-cancer effect.
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Figure 8 Treatment with IFN-a does not alter the GTPase activity of Ras.
Jurkat cells were grown for 48 h in complete RPMI medium in the presence
or absence of 30 ng ml–1 IFN-a, and subsequently metabolically labelled with
radioactive orthophosphoric acid. Whole-cell lysates were prepared before
and after stimulation of the IFN-a-treated and untreated cells with cross-
linked anti-CD3/CD4 antibodies. Equal amounts of whole-cell lysate were
used to immunoprecipitate Ras. Radioactive Ras-associated nucleotides
were eluted and separated by thin-layer chromatography. As shown,
treatment with IFN-a does not affect the ability of Jurkat cells to transiently
activate the GTPase activity of Ras in response to the stimulatory signal.
The results shown are representative of five independent experiments538 F Romerio et al
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